News & Press Releases

Mintz advised SightLine Applications, a leading developer of sensor processing software for autonomous and uncrewed systems, backed by Artemis, on its acquisition of Athena AI, an Australia-based specialist in AI-enabled computer vision and decision support for defense applications. 

Retail and Consumer Products Co-chair Chuck Samuels recently connected with The Bond Buyer about potential changes to the tax-exempt status of municipal bonds. He noted that private activity bonds (PABs) and the health care and higher education sectors are among the most vulnerable to the possible changes—particularly at the local district level.

JD Supra has recognized ten Mintz attorneys in its 2025 Readers’ Choice Awards. The awards recognize attorneys and firms whose articles on the JD Supra platform were most read by C-suite executives, in-house counsel, media, and other professionals during 2024. 

Mintz is a finalist for the “Life Sciences IP Firm of the Year” category in the inaugural Life Sciences Patent Network (LSPN) Awards USA 2025. The awards are organized by Life Sciences Intellectual Property Review and celebrate excellence across the industry—from trailblazing individuals to firms redefining the boundaries of life sciences IP. Judged by an independent panel of experts, the program highlights innovation, dedication, and the unsung heroes driving progress in the life sciences patent community.

A team of attorneys in Mintz’s renowned Patent Litigation Practice, led by Intellectual Property Division Chair Michael Renaud, was recognized as a ‘Litigator of the Week Runner-Up’ by The Am Law Litigation Daily for securing a significant defense victory for Juul Labs at the US International Trade Commission. The article highlights that the “full commission affirmed an administrative law judge’s decision finding that Juul didn’t infringe upon patents held by Altria’s NJOY covering certain vaporizer and cartridge technology, preventing any potential exclusion order.”

Life Science Litigation Practice Chair and Patent Litigation Practice Co-chair Sige Gutman recently spoke with Life Sciences Intellectual Property Review about the latest federal developments impacting the US Patent and Trademark Office, including hiring freezes, layoffs, the elimination of non-essential functions, and a return-to-office directive. The article analyzes the potential implications of the changes, particularly for pharma and biotech companies, as patent pendency times are already increasing due to a high volume of recent applications.